Effect of Saffron versus placebo on prevention of postpartum blues in primiparous women referring
Not Applicable
Recruiting
- Conditions
- Postpartum blues.Postpartum mood disturbanceO90.6
- Registration Number
- IRCT20120215009014N336
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Age of 18 to 35 years
Primiparous
Singleton
Term pregnancy
Wanted pregnancy
The first marriage
Normal delivery
Exclusion Criteria
Mental disease
Chronic diseases such as diabetes, hypertension, cardiovascular disease,
History of infertility
Hospitalization of the newborn in the intensive care unit
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean score of postpartum blues. Timepoint: Before the intervention and on 1, 5, 10 and 14 days after the intervention. Method of measurement: Using General Health Questionnaire (GHQ).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of saffron's active compounds (e.g., crocin, crocetin) may influence postpartum blues (O90.6) pathophysiology?
How does saffron's efficacy in preventing postpartum mood disturbance compare to standard-of-care antidepressants like SSRIs?
Which biomarkers (e.g., estrogen, serotonin, inflammatory cytokines) predict response to saffron in postpartum women (IRCT20120215009014N336)?
What are the safety profiles and adverse event management strategies for saffron supplementation in primiparous women?
What combination therapies or herbal alternatives (e.g., omega-3, St. John's Wort) synergize with saffron for postpartum blues prevention?